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As the threat of Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency
Syndrome (AIDS) persists to rise, effective drug treatments are required to treat
the infected people. Even though combination antiretroviral therapy (cART) provides
stable viral suppression, it is not devoid of undesirable side effects, especially in
persons undergoing long-term treatment. The present therapy finds its limitations in the
emergence of multidrug resistance and accordingly finding new drugs and novel targets
is the need of the hour to treat the infected persons and further to attack HIV reservoirs in
the body like brain, lymph nodes to achieve the ultimate goal of complete eradication of
HIV and AIDS. Natural products such as plant-originated compounds and plant extracts
have enormous potential to become drug leads with anti-HIV and neuroprotective
activity. Accordingly, many research groups are exploring the biodiversity of the plant
kingdom to find new and better anti-HIV drugs with novel mechanisms of action and for
HIV-associated neurocognitive disorders (HAND). The basic challenge that still persists is
to develop viral replication-targeted therapy using novel anti-HIV compounds with new
mode of action, accepted toxicity and less resistance profile. Against this backdrop,
the World Health Organization (WHO) suggested the need to evaluate ethno-medicines
for the management of HIV/AIDS. Consequently, there is need to evaluate traditional
medicine, particularly medicinal plants and other natural products that may yield effective
and affordable therapeutic agents. Although there are a good number of reports on
traditional uses of plants to treat various diseases, knowledge of herbal remedies used
to manage HIV/AIDS and HAND are scanty, vague and not well documented. In this
review, plant substances showing a promising action that is anti-HIV and HAND will be
explored along with what they interact. Since some plant substances are also known
to modulate several cellular factors which are also involved in the replication of HIV
and hence their role as potential candidates will be discussed. HIV/AIDS being an
exceptional epidemic, demands an exceptional approach and that forms very much
focus for the current review.
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INTRODUCTION
Since its ﬁrst discovery in 1981, Human Immunodeﬁciency Virus
(HIV)/Acquired Immunodeﬁciency Syndrome (AIDS) has killed
more than 25 million people worldwide and is today the major
threat to human health. However, due to the introduction of
highly active antiretroviral therapy (HAART) as well as the
impact of preventive measures, the prevalence and incidence
of HIV have declined globally over the last decade except for
parts of Eastern Europe and Central Asia where a slight increase
has been observed (UNAIDS, 2010; Cohen, 2012; Futterman,
2012; Kumari and Singh, 2012; Saxena et al., 2012). Even though
HAART provides stable viral suppression, it is not devoid of
undesirable side eﬀects, especially in persons undergoing long-
term treatment. The present therapy ﬁnds its limitations in the
emergence of multidrug resistance and accordingly ﬁnding new
drugs and novel targets is the need of the hour to treat the
infected persons and further to attack HIV reservoirs in the
body like brain, lymph nodes to achieve the ultimate goal of
complete eradication of HIV and AIDS (Vermani and Garg,
2002; Chinsembu and Hedimbi, 2010). Nature has always been
considered a basis for providing resources that can be used to
ﬁght oﬀ infections and treat diseases. Among these resources
there have been ﬁndings of medicinal plants that have anti-
HIV properties with low levels of toxicity. For the management
of HIV/AIDS, in 1989 the World Health Organization (WHO)
had declared the necessity to assess ethnomedicines and other
natural products. To quote: “In this context, there is need
to evaluate those elements of traditional medicine, particularly
medicinal plants and other natural products that might yield
eﬀective and aﬀordable therapeutic agents. This will require
a systematic approach” (World Health Organization [WHO],
1989a,b). Moreover, because they are fairly not as expensive
and have less side eﬀects, phytomedicines are retrieving patient
approval (Vermani and Garg, 2002; Short, 2006). Medicinal
eﬀects of plants incline to stabilize physiological function and ﬁx
the fundamental cause of the condition (Murray and Pizzorno,
1999). Recently, there has been a sustained bio prospective eﬀort
to isolate the active leads from plants and other natural products
for treatment of HIV and management of AIDS (Asres et al.,
2001; Vermani and Garg, 2002) and also screening of plants based
on ethnopharmacological data enhances the ability of discovering
novel anti-HIV compounds (Fabricant and Farnsworth, 2001;
Farnsworth, 2007). Indigenous knowledge of medicinal plants
further provides leads toward therapeutic concept, thereby
accelerating drug discovery. Thus, it is essential to explore for new
antiretroviral agents which can be combined with or substitute
the present resource of drugs against HIV (Klos et al., 2009).
Also, due to the widespread infection of HIV there has been a
determination for the discovery and use of medicinal agents that
can inhibit the virus. HIV type-1 (HIV-1) displays extraordinary
genetic variation and can be phylogenetically classiﬁed into three
distinct groups and several subgroups (A–K) across the globe.
While HIV-1 clade C dominates the HIV-1 epidemic worldwide
with more than 50% of the total viral infections, predominantly
in Southern Africa, India, and other parts of Asia, HIV-1 subtype
B is mainly found in (Western) Europe and in the Americas,
accounting for about 10% of the total infections (Rambaut
et al., 2001; Hemelaar et al., 2011; UNAIDS, 2011; Hemelaar,
2012; Reddy et al., 2012). In places like Brazil, clade C viruses
have been spreading rapidly to replace the previously dominant
clade B epidemic (Buonaguro et al., 2007; Gandhi et al., 2009;
de Oliveira et al., 2010). The virus basically utilizes the host’s
cellular machinery for its own replication leading to extensive
viral and host interactions during its life cycle (Kitchen et al.,
2001; Lawn et al., 2001; Valenti, 2001; An et al., 2004; Resh,
2005; Broder, 2009; Gandhi et al., 2010). Some of the cellular
factors aid replication while others are inhibitory (Balzarini,
1994; Mohri et al., 2001; Benito et al., 2004; Petrovas et al.,
2006; Appay et al., 2007; Samikkannu et al., 2010). All these
mechanisms lead to chronic immune activation, the key factor
in HIV-1 immunopathogenesis. The disease progression (Clerici
et al., 1996; Rodriguez et al., 2006; Schader and Wainberg, 2011;
Wayengera, 2011) is associated with the gradual T lymphocyte
decline, ﬁrst taking toll of helper CD4+ T cells and then the
cytotoxic CD8+ T cells. The pronounced decline of CD4+
T cells occurs due to the destruction of both infected and
uninfected cells mainly because of apoptosis of activated cells,
diminished hematopoiesis and thymic maturation. Apart from
inducing immune dysfunction, HIV-1 infection aﬀects neuronal
function by signiﬁcantly increasing several cellular proteins in
the brain, including amyloid precursor protein (APP), especially
in the axons present in the subcortical white matter tracts (Esiri
et al., 1998; Green et al., 2005; Soontornniyomkij et al., 2012).
During HAART therapy HIV persists in the brain and local
inﬂammatory responses to the virus can lead to higher APP
production and β-amyloid deposition which may lead to the
progression of Alzheimer’s disease and HAND (Giunta et al.,
2011). Accordingly, ﬁnding new drugs and novel targets is the
need of the hour to treat the infected persons and further to
attack HIV reservoirs in the brain to achieve the ultimate goal
of complete eradication of HIV and AIDS.
Extensive attention has been given to the pathogenesis
of HIV-1 infection and associated immunologic mechanisms,
however, the basic challenge that still persists is to develop viral
replication-targeted therapy using novel anti-HIV compounds
with new mode of action, accepted toxicity, and less resistance
proﬁle. Accordingly, in this review, plant substances showing
a promising anti-HIV activity and HAND will be summarized
along with the targets they interact including the speciﬁc
objectives for the pursuit of plants and other natural products
with identiﬁed active substances and mechanisms as well as those
with unidentiﬁed active mechanisms against HIV, AIDS, and
other neurocognitive disorders.
HIV-ASSOCIATED NEUROCOGNITIVE
DISORDERS (HAND) AND
ANTIRETROVIRAL THERAPY (ART)
Individuals infected with HIV have conditions of ﬂuctuating
degrees of impairment of cognition and associated functioning
and can develop HIV-associated neurocognitive disorders
(HAND; Antinori et al., 2007). Invasion and replication of HIV
Frontiers in Microbiology | www.frontiersin.org 2 January 2016 | Volume 6 | Article 1444
Kurapati et al. Natural Products and Anti-HIV Agents
in the brain parenchyma is accomplished by brain perivascular
macrophages, endogenous microglia, and some astrocytes that
are infected and can initiate the neuropathogenesis of HAND
(Kaul, 2009; McArthur et al., 2010). Immune activation of
resident glia and neuroinﬂammation are associated with this
infection and neuronal injury. The general occurrence of
HAND and related diseases continue to be at high levels even
with the extensive use of antiretroviral therapy (ART) that
has radically reduced the occurrence of the severest form of
HAND, HIV-associated dementia (HAD; Sacktor et al., 2002;
McArthur et al., 2004; Nath et al., 2008; Heaton et al., 2010).
The persistence of this high risk for HAND in individuals
experiencing eﬀective control of systemic HIV viral load is
incompletely explained, and suggested factors include eﬀects
of aging on brain vulnerability, persistence of HIV replication
in brain macrophages, evolution of highly neurovirulent CNS
HIV strains, and even long-term CNS toxicity of ART (Heaton
et al., 2010, 2011). The features linked with increasing the
inﬂammatory setting within the CNS and HIV replication
are what drive the pathogenesis of HAND. Neuronal damage
associated with HAND can be augmented by subordinate
eﬀects of aging, movement of activated monocytes, systemic
immune activation and drug abuse and can continue in spite
of the eﬀective systemic control of HIV replication by ART
(Gannon et al., 2013). Active complementary neuroprotectants
are substances that can overturn systemic immune activation
and associated inﬂammation both systemically and within the
CNS (Kaul and Lipton, 2006; Kraft-Terry et al., 2009; Grovit-
Ferbas and Harris-White, 2010; McArthur et al., 2010). Drugs
that aim toward these cellular pathways could quickly ease testing
and application of possible complementary neuroprotective
approaches against HAND. Prevention and treatment of HAND
requires strategies aimed at suppressing CNS HIV replication
and eﬀects of systemic and CNS inﬂammation in aging and
substance-abusing HIV populations. Use of improved CNS-
penetrating ARTmust be accompanied by evaluation of potential
ART neurotoxicity.
FACTORS AND NEUROTOXIC
COMPOUNDS INDUCING
HIV-ASSOCIATED NEUROCOGNITIVE
DISORDERS
After initial infection and seroconversion, HIV usually reaches
the brain. Infected monocytes migrating across the blood–brain
barrier (BBB), which can be seen as a “Trojan horse” mechanism,
is one concept suggested for potential viral entrance. After these
infected monocytes migrate across the endothelium, they settle
as infected perivascular macrophages. It has been proposed that
the virus is spread by cell-to-cell interaction between microglia
cells and macrophages (Kaul et al., 2001). The main cell types
that upkeep viral replication in the brain are multinucleated giant
cells (fused microglia cells and macrophages) and macrophages
in the perivascular spaces (Gonzalez-Scarano andMartin-Garcia,
2005). A multifaceted cascade is prompted within the brain
with recurrent exposures and heightened viral replication within
microglia. Inside the brain tissue is where viral proteins are
released which stimulate astrocytes and microglia to produce
cytokines, chemokines, and other inﬂammatory agents (Nottet
and Gendelman, 1995; Achim and Wiley, 1996). Release of viral
proteins is further stimulated by these cell-encoded indicators
that support the increase of HIV replication in microglia cells.
This can produce a toxic eﬀect on neurons, causing neuronal
dysfunction and neuronal loss. Nevertheless, when a collection
of these factors are existing along with the HIV infection,
a distinctive neuropathological signature is seen. Pathological
alterations are usually minor with irregularities mostly taking
place in basal ganglia, brain stem, central white matter, frontal
cortices, thalamus, and eventually leading to HAND (Sharer,
1992). There are studies exploring the associated risk factors for
the neurocognitive disorders in HIV patients and found that in
some but not in all studies, CD4 nadir count (Munoz-Moreno
et al., 2008; Ellis et al., 2011; Heaton et al., 2011) and detectable
HIV plasma viral load (Tozzi et al., 1999; Chang et al., 2002;
Devlin et al., 2012), have been associated with neurocognitive
impairment (Gonzalez et al., 2003; Paul et al., 2005; Vitiello et al.,
2007; Ettenhofer et al., 2009; Simioni et al., 2010). Shortening
in telomere length (TL), which has been used as a biomarker
of aging, has also been reported in individuals with an HIV+
status (Zanet et al., 2012; Malan-Muller et al., 2013; Pathai et al.,
2013). Also, shortened TL reported to increase the neurocognitive
impairment and risk of dementia in non-HIV populations (von
Zglinicki et al., 2000; Panossian et al., 2003; Honig et al., 2006)
which can be a marker for atypical age-related cognitive decline
(Martin-Ruiz et al., 2006; Valdes et al., 2008; Yaﬀe et al., 2009).
NATURALLY DERIVED ANTI-HIV AGENTS
The following natural products namely Calanolides (Coumarins),
Betulinic acid (a Triterpene), Baicalin (a Flavonoid), Polycitone
A (an Alkaloid), Lithospermic acid (a Polyphenolic) can be
mentioned as promising for anti-HIV agents (Figure 1) whereas
Withanolides (Steroidal lactones; Figure 2) for HIV-associated
neurocognitive disorders.
Coumarins
An example of non-nucleoside speciﬁc reverse transcriptase
inhibitors (NNRTI) of the virus are calanolides which are a
type of coumarin derived from diﬀerent tropical tree species of
the Calophyllum (Clusiaceae family; Dharmaratne et al., 2002).
Calanolide A (Figure 1), (Vlietinck et al., 1998), Calanolide
B and its derivative 7,8-dihydrocalanolide B can prevent
cytopathogenic eﬀects of HIV-1 on host cells and are attained
from the Calophyllum lanigerum. Cordatolide A and B are
similar in structure to Calanolides and can inhibit replication of
HIV-1. These compounds are extracted from the Calophyllum
cordato-oblongum (Lee et al., 1994). Suksdorﬁn (Yu et al.,
2003) is another compound that also has inhibitory eﬀects on
replication of the virus in the T cell line and is a pyrocoumarin
derivative that can be extracted from the Angelica morii and
Lomatium suksdorﬁi fruits from the Apiaceae family (Zhou et al.,
2000).
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Terpenes
Antiretroviral activity with diverse mechanisms of action have
been observed with some triterpenoids. Betulinic acid (Figure 1),
platanic and oleanolic acid tested in H9 lymphocyte cells have
shown inhibition of HIV and can be obtained from the leaves
of Syzigium claviﬂorum (Min et al., 1999). Inhibition of HIV-
1 replication in these cells were observed with oleanolic acid
which can be attained frommethanolic extract of theXanthoceras
sorbifolia, wood from the Sapindaceae family (Kashiwada et al.,
1998). Potent inhibitory activity against HIV-1 protease has been
seen with maslinic acid derived from the Geum japonicum (Xu
et al., 1996). Anti-HIV replication activity in H9 cells is observed
with Celasdin B that is derived from ethanolic extract of the
Celastrus hindsii which is from the Celastraceae family (Yao-
Haur and Li-Ming Yang, 1997). The protostanes, garcisaterpenes
A and C can suppress HIV-1 RTase activity and are obtained
from the ethyl acetate extract of the stems and bark of Garcinia
speciosa (Rukachaisirikul et al., 2003). Lanostane-type triterpene
has also shown inhibition of HIV replication in H9 cells and
is a suberosol obtained from ethanolic extract of the leaves
and stems of Polyalthia suberosa from the Annonaceae family
(Li et al., 1993). Triterpene lactone, lancilactone C extracted
from the roots and stems of Kadsura lancilimba is another
compound that restrains HIV replication in these cells (Chen
et al., 1999). The 12-O-tetradecanoylphorbol-13-acetate (TPA), a
FIGURE 2 | Chemical structure of Withanolide A. [Reproduced with
permission from Kurapati et al. (2014).]
phorbol diester, can inhibit cytopathogenic eﬀects of HIV-1 and
is attained from methanolic extract of Croton tiglium from the
Euphorbiaceae family. Prostratin, a phorbol ester also has anti-
HIV properties and is extracted from Homalanthus nutans from
the Euphorbiaceaen family (El-Mekkawy et al., 2000).
Flavonoids
Favorable anti-HIV activity have been exhibited by ﬂavonoids
and associated polyphenols. They are known for having
FIGURE 1 | Structural formulae of representative anti-HIV natural products.
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antioxidant properties and have been found to show antiviral
activity in diﬀerent cell cultures (Orhan et al., 2010). Baicalin
(Figure 1) inhibits HIV replication in PBMC in a dose dependent
fashion and is an anti-HIV ﬂavonoid extracted from Scutellaria
baicalensis (Ohtake et al., 2004). The 6,8-diprenylaromadendrin
and 6,8-diprenylkaempferol, prenylated ﬂavonoids, also show
anti-HIV activity in the XTT-based, whole-cell screen and are
derived from the extract of Monotes africanus (Meragelman
et al., 2001). Flavonoid gallate ester and quercetin 3-O-(2-
galloyl) a-L-arbinopyranose can inhibit integrase activity of HIV-
1 and are obtained from ethanolic extract of Acer okamotoanum
from the Aceraceae family (Kim et al., 1998). Hinokiﬂavone,
robustaﬂavone, and biﬂavonoids have demonstrated inhibition
of the polymerase of HIV-1 reverse transcriptase (RT) and are
attained from methanolic extracts of leaves and twigs of Rhus
succedanea from the Anacardiaceae family (Lin et al., 1997).
Wikstrol B, a biﬂavonoid, also shows anti-HIV activity and can
be isolated from extracts of roots of Wikstroemia indica from
the Thymelaeaceae family (Hu et al., 2000). Xanthohumol, a
prenylchalcone that has demonstrated inhibition of HIV-1 and
is extracted from hops Humulus lupulus (Wang et al., 2004).
Alkaloids
Diﬀerent types of alkaloids have shown anti-HIV activity.
One of the natural products with interesting activity on RT
is polycitone A (Figure 1), an aromatic alkaloid isolated
from the marine ascidian Polycitor sp. Polycitone A exhibits
potent inhibitory activity on both RNA- and DNA-directed
DNA polymerases (Loya et al., 1999). Papaverine, an alkaloid
can inhibit HIV replication and is extracted from Papaver
sominiferum from the Papaveraceae family. Buchapine is a
type of quinolone that has shown inhibition of cytopathogenic
eﬀects of HIV-1 and is isolated from Eodia roxburghiana
(McCormick et al., 1996). Nitidine also shows anti-HIV activity
and is extracted from the roots of Toddalia asiatica of the
Rutaceae family (Tan et al., 1991). A piperidine ﬂavone related
alkaloid O-demethylbuchenavianine shows a hindrance to the
activity of HIV and is attained from Buchenavia capitata of
the Combretaceae family (Beutler et al., 1992). Harmine has
shown inhibition of HIV replication in H9 cells and is derived
from Symplocos setchuensis (Ishida et al., 2001). 1-Methoxy
canthionone has anti-HIV properties and is obtained from
Leitneria ﬂoridana (Xu et al., 2000). Hypoglaumine B, Troponine
B, andTroponine A are sesquiterpene pyridine alkaloids that have
shown to also possess anti-HIV properties and are isolated from
Tripterygium wilfordii and Tripterygium hypoglaucum (Duan
et al., 2000).
Phenolics
Because of heightened phytohaemagglutinin-induced
lymphocytes proliferation, prolonged administration of
polyphenol-rich fruit juices is believed to be promising to
HIV-positive individuals. There are several tannins and related
phenolic substances which show virucidal eﬀects in several
viral systems. Lithospermic acid (Figure 1) isolated from
Salvia miltiorrhiza has strong anti-HIV activity in H9 cells
(Abd-Elazem et al., 2002). Punicalagin, chebulagic acid, and
punicalin are hydrolysable tannins that demonstrate anti-HIV
activity and come from Terminalia chebula (Lim et al., 1997).
Repandusinic acid has shown inhibition of HIV-1 RTase and is
extracted from Phyllanthus niruri of the Euphorbiaceae family
(Ogata et al., 1992). Monopotassium and monosodium salts
of isomeric caﬀeic acid tetramer have shown inhibition of
HIV replication and are obtained from the aqueous acetone
extract of Arnebia euchroma of the Boraginaceae family
(Kashiwada et al., 1995). Camellia-tannin H shows inhibition
of the HIV-1 protease and is extracted from the pericarp
of Camellia japonica (Fuller et al., 1999). Galloyl glucoses
and gallic acid exhibited a hindrance of HIV integrase and
are extracted from Terminalia chebula of the Combretaceae
family (Ahn et al., 2002; Park et al., 2002). Mallotojaponin is
a dimeric phloroglucinol derivative that inhibits activity of
HIV-1 RTase and is extracted from the pericarps of Mallotus
japonicus. The curcuminoids have shown inhibition of HIV-1
and HIV-2 protease and are extracted from rhizomes of Curcuma
longa (Roth et al., 1998). Peltatol A is a prenylated catechol
dimer that shows anti-HIV activity and is extracted from
Pothomorphe peltata of the Piperaceae family (Gustafson et al.,
1992).
Lignans
Several lignans have antiviral properties (Charlton, 1998).
Phyllamyricin B and its lactone retrojusticidin B display
inhibition of HIV-RTase activity and are obtained from
chloroform extract of Phyllanthus myrtifolius/P. urinaria of the
Euphorbiaceae famly (Liu and Li, 1995). Anolignan B, anolignan
A, and dibenzylbutadiene lignans have shown inhibition of HIV-
1 RTase and are extracted from Anogeissus acuminata (Rimando
et al., 1994). Gomisin has been found to be one of the strongest
inhibitors of HIV replication and is obtained from Kadsura
interior (Chen et al., 1997).
Quinones
Plumbagin, 1,4-naphthoquinone, juglone, and vitamin K3 are
naphthoquinones that all demonstrate HIV inhibitory activity
(Min et al., 2002). Conocurvone is a trimeric naphthoquinone
that shows eﬀective anti-HIV activity and is extracted from
Conospermum incurvum of the Proteaceae family (Decosterd
et al., 1993).
Saponins
Actein is a tetracyclic triterpenoid saponin that exhibits strong
anti-HIV activity and derives from the rhizome of Cimicifuga
racemosa (black cohosh), (Sakurai et al., 2004).
Xanthones
Swertifrancheside is a ﬂavonone–xanthone glucoside that has
shown inhibition of HIV-1 RTase and is extracted from Swertia
franchetiana (Wang et al., 1994). Macluraxanthone B is a
prenylated xanthone that also shows anti-HIV activity and
is extracted from Maclura tinctoria of the Moraceae family
(Groweiss et al., 2000).
Table 1 list the ongoing or completed clinical trials of anti-HIV
eﬀect of natural substances.
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Ameliorating Effects ofWithania
somnifera (Ashwagandha) Root Extract
on HIV-Associated Neurocognitive
Disorders
It is well known that use of alcohol and drugs of abuse are
associated with increased risk of attaining HIV-1 infection as well
as augmented disease progression (Nair et al., 2004, 2009; Dhillon
et al., 2007; Atluri et al., 2014). Further, studies have shown that
use of alcohol and drugs of abuse are also risk factors for dementia
and other cognitive disorders (Brandt et al., 1983; Darke et al.,
2000; Atluri et al., 2015; Hidalgo et al., 2015; Roy et al., 2015;
Sagar et al., 2015; Samikkannu et al., 2015a,b). Along this line,
impacting more than 15 million people worldwide, Alzheimer’s
disease (AD) is the most frequent form of senile dementia
(Kim et al., 2011). This number will surely increase quickly
in the future with augmented life expectancy. The pathological
hallmarks of AD are complex and include neuronal degeneration,
neuro-inﬂammation, toxic β-amyloid (AB) plaques, abnormal
neuroﬁbrillary tangles, and a decline of neurochemicals which are
essential for neuronal transmission (McArthur et al., 2003, 2010;
Robertson et al., 2007; Heaton et al., 2010, 2011). The precise
mechanisms of β-amyloid that lead to neurotoxicity continue
to be a question but its cytotoxicity to neuronal cells has been
TABLE 1 | Summary of clinical trials of natural products for treating HIV and AIDS.
Natural product and
Country
Design Aim Treatment plan Study phase
and Reference
Echinacea purpurea-
Spain
Non-Randomized, Single
Group Assignment two arms,
Open Label trial
To characterize drug interactions
between medicinal herb Echinacea
purpurea widely used by HIV infected
patients and its interaction with
protease inhibitor Darunavir/Ritonavir
Recruiting 15 HIV-1 infected patients on
antiretroviral therapy with darunavir/ritonavir
600/100 mg twice a day for 4 weeks. Treating
these patients with Echinacea purpurea for
14 days, 500 mg every 6 h.
Phase 4 (Molto,
2010)
Echinacea purpurea-
Spain
Non-Randomized, Single
Group Assignment two arms,
Open Label trial
To characterize drug interactions
between one medicinal herb:
Echinacea purpurea and the protease
inhibitor etravirine
Recruiting 15 HIV-infected patients on stable
antiretroviral therapy including etravirine at the
dosage of 200 mg twice daily during at least
4 weeks. Treating these patients with
Echinacea purpurea root (500 mg every 8 h) in
addition to their antiretroviral treatment, from
day 1 until 2 weeks later (day 14).
Phase 1
(Fundacio Lluita
Contra la SIDA,
2011)
Triptolide woldifiion-
China
Randomized, Factorial
Assignment, two arms,
Open Label trial
To evaluate the effects and side effects
of ARV treatment in acute HIV-1
infection phase, and to evaluate the
impact of Triptolide wilfordii on HIV-1
reservoir
Recruiting 18 naive-treatment patients with
acute HIV-1 infection phase, and treating with
the antiretroviral drugs (Tenofovir plus
lamivudine plus Lopinavir/ritonavir plus
raltegravir). Six months later, treating these 12
patients with Triplitode.
Phase 3 (Li,
2014)
Triptolide wilfordii-
China
Randomized, Crossover
Assignment two arms,
Double Blind,
placebo-controlled trial
To evaluate impact of Triptolide wilfordii
on T-cell immune activation and
inflammation biomarkers in HIV-infected
immunological non-responders
Recruiting 120 patients from 4 HIV/AIDS clinical
centers and treating the invention group with
Triptolide wilfordii (20 mg tid po) for 24 weeks.
Phase 1 (Lu,
2013)
Phase 2
Tripterygium wilfordii
Hook F (TwHF)- China
Parallel, Non-Randomized, two
arms, open label trial
Safety and Efficacy Study of
Tripterygium wilfordii Hook F Extract in
cART-Treated HIV Patients With Poor
Immune Responses
Recruiting 23 patients immunological
non-responders, 19 receive TwHF extract
(10 mg tid po) plus current cART, while four
patients continue their current cART for
12 months.
(Murray et al.,
2010; Piconi
et al., 2011)
Moringa oleifera-
Zimbabwe
Observational, Case-Crossover,
Prospective study
To study the effect of simultaneous
treatment with antiretroviral drugs
(nevirapine and efavirenz) and the herb
Moringa
Recruiting 19 HIV-positive patients to compare
the steady-state pharmacokinetics of nevirapine
and efavirenz before and after supplementation
with Moringa oleifera leaf powder.
(Sebit et al.,
2000)
Immunity 1 (Fuzheng
1)- China
Multi-center, Randomized, two
arms, Double-blind,
Placebo-controlled Clinical
Trials
Study the effect of Immunity 1 (Fuzheng
1) on Immune Reconstitution of HIV
Patients
Recruiting 60 HIV-positive patients (WHO
clinical stage I and II) and treating with Fuzheng
1 (8.75 g twice a day) half an hour before
breakfast and dinner, mixing with water, for six
successive cycles of 30 days.
(Wang, 2009a)
Immunity 1 and 3
(Fuzheng 1 and 3):
Composed of herbs
which have tonic and
detoxific function-
China
Multi-center, Randomized,
three arms, Double Blind,
placebo-controlled trial
To evaluate the efficacy and safety of
combination of Traditional Chinese
Medicine (TCM) and Highly Active
Antiretroviral Therapy (HAART) on
immune reconstitution of HIV/AIDS
patients
Recruiting 180 HIV infected patients and
treating with Fuzheng 1 or 3 (8.75 g/twice a
day) half an hour before breakfast and dinner,
mixing with water, for six successive cycles of
30 days.
(Wang, 2009c)
Immunity 2 (Fuzheng
2)- China
Parallel, randomized, two arms,
Double Blind,
placebo-controlled trial
To evaluate the effect of immune 2
(Fuzheng 2) on immune reconstitution
of adult HIV/AIDS patients who have
received HAART
Recruiting 180 HIV infected patients and
treating with Fuzheng 2 (6.25 g twice a day) half
an hour before breakfast and dinner, mixing
with water, for six successive cycles of 30 days.
(Wang, 2009b)
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acknowledged as one of the main features in AD pathology
(Sacktor et al., 2001). In AB-induced cytotoxicity it seems
that some of the possible mechanisms involved are oxidative
stress and free radical formation (Xu and Ikezu, 2009). In HIV
infection, neuronal degeneration is also a main feature. In AIDS
patients, a noteworthy increase in brain APP has been observed
especially in the axons found in the subcortical white matter
tracts (Esiri et al., 1998; Green et al., 2005; Anthony et al., 2006;
Lindl et al., 2010). HIV can persist in the brain during HAART
therapy and local inﬂammatory responses can cause an increase
of APPproduction and exposure to amyloid deposition (Anthony
and Bell, 2008). During HIV induced neuronal degeneration and
development of Alzheimer’s disease, β- amyloid buildup may be
used as an indicator of early neuronal degeneration.
A medicinal plant that has many therapeutic properties
such as antioxidant and immunomodulatory properties, memory
enhancer, nerve tonic and antistress is Withania somnifera (L.)
Dunal, also known as ‘ashwagandha’ (ASH) or ‘Indian ginseng’
and has had a signiﬁcant upsurge in pharmacological studies in
the recent years (Mishra et al., 2000; Kulkarni and Dhir, 2008). In
cultured neurons and in rodents injected with Aβ 25–35, neurite
outgrowth has been induced by withanoside IV and withanolide
A extracted from the roots (Kuboyama et al., 2005). Root
extracts from this species have also been shown to signiﬁcantly
reduce the number of hippocampal degenerating cells in the
brains of stressed rodents (Jain et al., 2001) and were neuro-
protective in animal models of Parkinson’s disease (Sankar et al.,
2007). Accumulation of oligomers and β-amyloid peptides (Aβ),
behavioral deﬁcits and plaque pathology have been upturned
in the brains of old and middle-aged APP/PS1 Alzheimer’s
disease transgenic mice with the oral dispensation of a semi-
puriﬁed extract of the root of W. somnifera mainly involving
withanosides and withanolides (Sehgal et al., 2012). However,
there is a scarcity of data on the mechanisms related to the
possible defensive eﬀects of W. somnifera root against HIV-1Ba-
L (clade B) infection and β-amyloid (1–42)-induced cytotoxicity.
In a confocal microscopic analysis, β-amyloid treated SK-N-
MC cells (neuronal cell line) showed a reduction in spine area,
dendrite diameter, spine density, total dendrite, and a loss of
spines when compared to untreated cells (Kurapati et al., 2013).
Nonetheless, the toxic eﬀects were counteracted when ASH
root extract was added to β-amyloid treated cells (Kurapati
et al., 2013). Further, as demonstrated by increased trypan blue
stained cells, β-amyloid prompted cytotoxic eﬀects in SK-N-MC
cells. Nevertheless, the toxic eﬀects were neutralized when ASH
root extract was added to β-amyloid treated cells (Figure 3),
(Kurapati et al., 2014). This observation was supported by
the levels of acetylcholinesterase activity, cellular localization
of β-amyloid, and MTT formazan exocytosis, conﬁrming the
defensive eﬀects of ASH root extract against β-amyloid prompted
toxicity (Kurapati et al., 2013, 2014). Also, Withanolide A
(WA; Figure 2) demonstrated the same pattern using MTT
assay as a parameter and is a reﬁned component of ASH
(Figure 4) (Kurapati et al., 2014). These observations suggests
that neuroprotective properties of ASH root extract may oﬀer
some clariﬁcation for the ethnopharmacological usages of ASH
in traditional medicine for cognitive and other HIV associated
neurodegenerative disorders and additionally ASH could be a
possible new drug to reduce the brain amyloid load and/or
improve the HIV-1 associated neurocognitive damages.
Apart from our studies on ASH, reports are scanty on
the eﬀect of natural compounds for the treatment of HIV
associated neurocognitive disorders. Ginkgo biloba has been
known as a traditional medicine for people with dementia.
Zou et al. (2007) reported that administration of EGb 761,
a standardized formulation of Ginkgo biloba extract, reported
to protect Tat transgenic mice from Tat-induced neuro toxic
eﬀects like developmental retardation, inﬂammation, death,
astrocytosis, and neuron loss by down-regulating the glial
ﬁbrillary acidic protein (GFAP) expression. In GFAP null Tat-
transgenic mice model, reduced Tat-induced neuropathological
phenotypes including macrophage/microglia activation, central
nervous system inﬁltration of T lymphocytes, and oxidative has
been reported.
Hypericum perforatum (St John’s Wort) extracts are generally
used for the treatment of mild to moderately severe depression.
Role of P27SJ, a protein present in a laboratory callus
culture of Hypericum perforatum was explored to control
HIV transcription and replication in microglia and astrocytes
(Darbinian-Sarkissian et al., 2006). This study reported that P27SJ
suppress transcription of the HIV-1 Genome/viral replication
(50%) by interacting, inhibiting the DNA-binding activity and
altering subcellular localization of CCAAT/enhancer-binding
protein beta (C/EBPb), a transcription factor that regulates
expression of the HIV-1 genome. Also, P27SJ reported to interact
with HIV-1 Tat and inhibits its activity on transcription of
HIV-1 LTR and relocalizing it to the cytoplasm. Therefore
P27SJ is a potential therapeutic agent for inhibiting the
HIV-1 induced neurotoxicity in the brain by suppressing
its replication and inhibiting inﬂammatory response induced
by proinﬂammatory Tat-inducible chemokines such as MCP-
1. Few studies reported the potential adverse St. John’s
Wort extracts drug reactions and interactions especially with
other antidepressants, with coumarin-type anticoagulants, the
immunosuppressants cyclosporine and tacrolimus, protease and
RT inhibitors used in anti-HIV treatment (Schulz, 2006).
For inhibiting the HIV replication in the brain or nullifying
the neurotoxicity induced by HIV replication and its proteins,
further studies are necessary to explore the neuroprotective
eﬀect of natural compounds like Sage (Salvia oﬃcinalis,
Salvia lavandulaefolia, Salvia lavandulifolia), Bacopa (Bacopa
monnieri), Gotu kola (Centella asiatica), which are being used
as a therapeutic alternative medicines for memory and cognitive
improvement.
PLANT COMPOUNDS TAKING ACTION
ON VIRAL MARKS AND ADVANTAGES
In the study of plant extracted anti-HIV compounds there have
been signiﬁcant improvements that are centered on their activity
in vitro and the mechanisms that are used. Some of these
compounds will be discussed in this review along with the viral
targets they interact with. Covering all the natural substances
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FIGURE 3 | Effect of ASH in reversal of β-Amyloid induced cell death. Treating the SK-N-MC cells with β-Amyloid (B) resulted in significant cell death when
compared to the untreated control cells (A). Treating the cells with ASH (C) and ASH plus β-Amyloid (D) exhibited good viability as evidenced by exclusion of trypan
blue dye. [Reproduced with permission from (Kurapati et al., 2014).]
that possess these anti-HIV properties is still a work in progress.
Most of these compounds interfere with early steps in the HIV
replication, such as the virus entry steps and on the viral enzymes
RT and integrase.
Virus Entry
Many protein interactions are involved in HIV entry and have
the potential to become targets for the development of new entry
blockers. TheHIV fusion inhibitor, Enfuvirtide (Jiang et al., 2002)
does not have oral bioavailability but requires two injections
per day and can cause signiﬁcant local side eﬀects. Compounds
that are recognized as strong inhibitors of HIV-1 and HIV-2
replication in vitro are sulfated polysaccharides (Witvrouw and
De Clercq, 1997; Lüscher-Mattli, 2000). These compounds exert
their anti-HIV properties by shielding oﬀ the positively charged
amino acids in the V3 loop of the glycoprotein gp120 from the
viral envelope of HIV (Witvrouw and De Clercq, 1997). The V3
loop is necessary for virus attachment to cell surface heparan
sulfate, a primary binding site, before more speciﬁc binding
occurs to the CD4 receptor of CD4+ cells. Ursolic acid, oleanolic
acid, betulinic acid and their derivatives have been the focus of
recent research on triterpenoids. Inhibition of HIV-1 protease has
been observed in vitro with these triterpenes. One of the many
betulinic acid derivatives that were synthesized in a structure-
activity relationship study, RPR103611, was chosen for additional
mechanistic research. Numerous important steps of the HIV life
cycle have been inhibited by ﬂavonoids. Viral protease has been
inhibited by taxifolin which is a ﬂavanone with an OH group
at position C-3′. Aromadendrin does not inhibit viral protease
or RT but can inhibit interactions between CD4 and gp120, is
more deﬁnite in its antiviral activity and is a ﬂavanone that
lacks an OH group at position C-3′ (Mahmood et al., 1997). The
(-)-epigallocatechin 3-O-gallate has demonstrated activity against
HIV-1 (De Clercq, 1995) such as a damaging eﬀect of virus
particles and post-adsorption entry and inhibition of RT and viral
protease (Yamaguchi et al., 2002). Flavonoids are recognized as
inhibitors of several enzymes including RT which is crucial for
HIV replication (Kitamura et al., 1998) viral protease (Xu et al.,
2000) and integrase (Kim et al., 1998).
Reverse Transcription
The viral reproductive cycle begins when the enzymes within the
nucleoprotein complex are activated after the virus enters the cell.
The viral RT transcribes the RNA genome of HIV into a double-
stranded DNA form after the nucleoprotein core of the virus is
disrupted. RNA reverse transcription to DNA, degradation of
RNA template by RN-ase H and duplication of the remaining
DNA strand are the three consecutive functions that are
controlled by the HIV-1- RT. The 4-propyldipyranocoumarins
or calanolides are natural products that have been considered to
be potential anti-HIV agents. (+)-Calanolide A (Chan and Kim,
1998) is signiﬁcantly more active on inhibition of HIV-1 RT when
compared to cordatolides A (Jiang et al., 2002) and B (Lüscher-
Mattli, 2000). Currently, to evaluate its pharmacokinetics and
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FIGURE 4 | Effect of Withanolide A on viability of SK-N-MC cells
treated with HIV-1Ba-L (clade B), Cocaine and Methamphetamine
(METH): SK-N-MC cells were infected with HIV in the presence of
Cocaine/METH. The MTT assay is showing that Withanolide A reverse the
neurotoxic effects on cell viability induced by HIV, Cocaine, METH and
combined treatment. Withanolide A alone showed significant increase in cell
viability. The values were expressed as percentage of cell viability compared to
control cells and are the mean ± SD of four experiments. ∗∗∗, ∗∗, ∗ indicates a
statistically significant difference (p,0.0001), (p,0.0006), and (p,0.0185),
respectively, compared to controls. WA, Withanolide A; CO, COC, Cocaine;
METH, Methamphetamine. [Reproduced with permission from Kurapati et al.
(2014).]
safety, (+)-calanolide A is being tested in clinical trials for both
HIV-infected and healthy volunteers (Creagh et al., 2001).
Integration
Besides protease and RT, integrase is the only enzyme that is
encoded by HIV-1. Strand transfer and 3′-processing are the
two steps for integration of viral DNA into host DNA and are
catalyzed by integrase. This enzyme ﬁrst cleaves the last two
nucleotides from each 3′-end of the linear viral DNA. Then the
nucleophilic attack of these 3′-ends on host chromosomal DNA
are involved in the subsequent DNA strand transfer reaction. The
l-chicoric acid was the most active inhibitor of HIV integrase
out of all the bis-catechols tested. Recently, due to its compelling
anti-HIV potential, MAP30 received a lot of attention and is a
plant protein of 30 kDa extracted from Momordica charantia L.,
(Lee-Huang et al., 1995; Sun et al., 2001). Moreover, this plant
protein toxicity is deﬁnite to HIV-infected cells, does not exhibit
opposing eﬀects on normal cells and is an inhibitor of HIV-1
integrase by rendering the HIV LTR an unsuitable substrate for
HIV integrase as well as DNA gyrase.
Transcription
Until levels of its trans-activator protein Tat rise, HIV-1
DNA transcription is low after integration of viral DNA into
the host genome. By binding to the transactivation response
element (TAR) at the 5′-end of the viral mRNA, Tat, an 86-
amino acid polypeptide, can increase the capacity of host RNA
polymerase (Ptak, 2002). The transcriptional activity of HIV-
1 long terminal repeat (LTR) can be stimulated by the Tat
protein after being released from HIV-1-infected cells and has
entered new cells in an active form (Mann and Frankel, 1991).
Between positions 133 and 104 of the HIV promoter, tannic
acid has been observed to have found a putative tannic acid-
responsive element and suppress 12-O-tetradecanoylphorbol 13-
acetate (TPA) – inducing HIV promoter activity (Uchiumi et al.,
1996). Furthermore, a number of natural substances related
to tannins were assessed for their HIV promoter repression
eﬀects (Uchiumi et al., 2003). Chalcones, 3-phenylcoumarins
and isoﬂavones have all successfully repressed TPA-induced HIV
promoter activity in a structure-activity relationship study.
CONCLUSION
Although, antiretroviral drugs can bring about the repression of
the serum load of the virus to undetectable levels, economical,
commercial, and political barriers have limited their accessibility
to a good part of the population suﬀering from the diseases.
Natural products, particularly those in traditional medicine have
supplied a basis of new drug candidates for many diseases
including HIV and other neurocognitive disorders. The number
of compounds exhibiting anti-HIV activity isolated from plants
is increasing gradually and due to their explicit activity, there are
several natural products have been used as primary compounds.
Since the resistance of HIV-1 to the antiretroviral drugs has
been increasing along with the necessity of agents that are not
as costly and toxic as the ones being used now, new treatments
with these natural products are needed. The basic challenge that
still persists is to develop viral replication-targeted therapy using
novel anti-HIV compounds with new mode of action, accepted
toxicity, and less resistance proﬁle. Against this backdrop, the
World Health Organization (WHO) suggested the need to
evaluate ethno-medicines for the management of HIV/AIDS.
Accordingly, there is need to evaluate traditional medicine,
particularly medicinal plants and other natural products that
may yield eﬀective and aﬀordable therapeutic agents (World
Health Organization [WHO], 2002; Jaco et al., 2004; Hedimbi
and Chinsembu, 2012). In this context, the above mentioned
results demonstrate that several plants, the majority of which
are usually utilized for the treatment of various illnesses, are
active against HIV. Since they are the indicators for the decision
making at various levels and the ﬁnding of new lead substances,
these reports are invaluable. The preparation, cytotoxicity, or
selectivity proﬁle of an antiviral substance should also be carefully
assessed before any further attention is given to it. However, in
repressing HIV progression and replication it should be stressed
that several natural products primarily extracted from plants have
demonstrated to be eﬀective. HIV/AIDS being an exceptional
epidemic, demands an exceptional approach and that forms very
much our current and future research.
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